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Abstract
Atopic dermatitis (AD) is a debilitating condition, and its management in both 
children and adults can be challenging for clinicians and patients alike. The current 
treatment options approved by the Food and Drug Administration (FDA) have 
variable efficacies, and long-term adverse effects, which further complicate the plan 
of management. There has been considerable progress towards the use of targeted 
medicines like biologicals and small molecular agents for atopic dermatitis. Various 
molecules targeting the TH2 pathway, JAK/STAT pathway, cAMP, IL-22, Il-12/IL-23 
and IgE, have been developed, and are being studied extensively in both adults and 
pediatric patients of atopic dermatitis. Currently, only Dupilumab is approved by 
the FDA for the treatment of moderate to severe refractory atopic dermatitis. The 
other biological agents are currently in phase 2 or phase 3 trials. There is a paucity of 
multicentric, large-scale studies on the above drugs, along with a lack of compara-
tive studies with the existing modalities of treatment. Therefore, more studies with 
a larger sample size and longer follow up periods are needed to determine their 
efficacy and long-term safety profiles. Overall, these agents are likely to be a part of 
the therapeutic armamentarium for atopic dermatitis in the near future.
Keywords: atopic dermatitis, biologicals, Dupilumab, Th2 pathway, JAK/STAT 
pathway
1. Introduction
Atopic dermatitis (AD) is a debilitating condition, and its management in both 
children and adults can be challenging for clinicians and patients alike. About 20% 
of patients with AD manifest with moderate to severe forms of the disease, which 
are refractory to conventional treatment. The current treatment options approved 
by the Food and Drug Administration (FDA) have variable efficacies, and long-
term adverse effects, which further complicate the plan of management [1].
There has been considerable progress towards the use of targeted medicines like 
biologicals and small molecular agents to block specific cytokines, their receptors, 
or transcription factors. The indications for these agents are also rapidly expanding, 
from adults to the pediatric population. Their formulations range from injections to 
oral tablets, and topical creams and ointments [2].
Advances in understanding the various immunopathological changes occurring 
in atopic dermatitis have allowed the identification of various therapeutic molecular 
targets and synthesis of various biological agents [1].
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2.  Classification of biological agents (based on their mechanism of 
action)
1. IgE directed therapy-Omalizumab
2. Th2 inhibitors:
• Anti IL-4-Dupilumab
• Anti IL-4/IL-13 agents-Lebrikizumab, Tralokinumab
• IL-31 directed therapy-Nemolizumab
3. Anti IL-12/23 agents-Ustekinumab
4. IL-22 blockade-Fezakinumab
5. Thymic stromal lymphopoietin directed therapy-Tezepelumab
6. JAK inhibitors-Tofacitinib, Abrocitinib, Delgocitinib, Upadacitinib,  
Ruxolitinib, Baricitinib
7. Miscellaneous agents
2.1 IgE directed therapy-Omalizumab
Omalizumab is a recombinant humanized monoclonal IgG1 antibody, which 
has been approved by the FDA for the treatment of moderate to severe persistent 
asthma and chronic spontaneous urticaria. It has also been shown to be beneficial in 
chronic inducible urticaria, allergic rhinitis, eosinophilic esophagitis, food allergy, 
anaphylaxis, as premedication in allergen specific immunotherapy, Churg-Strauss 
disease, eosinophilic otitis media, allergic bronchopulmonary aspergillosis, chronic 
rhinosinusitis, bullous pemphigoid, contact dermatitis and atopic dermatitis [1].
Mechanism of action
It is composed of 5% murine and 95% human sequence. Omalizumab combines 
with the free, soluble IgE, blocking its binding to its receptors, and subsequently 
preventing allergen-induced mediator release.
It dramatically reduces the serum levels of free IgE (by 99% in the first two 
hours after administration), which then downregulates the expression of IgE 
high-affinity receptors on immune cells. It also decreases the expression of several 
cytokines (such as IL-5, 8, 13) and inhibits the recruitment of immune cells (T-cells, 
eosinophils, and macrophages) to the affected sites. Therefore, it inhibits both the 
immediate and the late inflammatory phases. It is also involved in apoptosis of mast 
cells and eosinophils.
Omalizumab in AD
Anti-IgE therapy in AD has shown conflicting results. Although most data from 
small randomized trials, case series and case reports documented clinical benefit 
and resolution of eczema, a small number of studies showed no improvement of 
disease with Omalizumab. Filaggrin mutations and raised serum IgE levels were 
associated with a poorer response to Omalizumab [3]. All of the studies noted the 
safety profile in both adult and pediatric population treated with Omalizumab. 
However, the variable response to treatment and lack of standardized dosing 
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protocols remain major drawbacks. Another notable conclusion of placebo-con-
trolled studies showed no significant improvement with Omalizumab compared to 
the control groups [1].
2.2 TH2 inhibitors
2.2.1 Anti IL-4 (Dupilumab)
Dupilumab was approved by the FDA in 2017 for the treatment of adults with 
moderate to severe refractory atopic dermatitis [1]. It was further approved in 
2020 for children aged 6 to 11 years with moderate-to-severe atopic dermatitis [4]. 
Currently, it is the only biological approved for the treatment of AD.
Dose—It is available as prefilled syringes containing 300 mg 0r 200 mg of 
the drug
• Adults and children (6–11 years weighing >60 kgs): Loading dose of 600 mg 
subcutaneously followed by 300 mg every 2 weeks
• Pediatric patients (weight > 30-<60 kgs)-400 mg s/c loading dose followed by 
200 mg every 2 weeks
• Pediatric patients (weight > 15-<30 kgs)-Loading dose of 600 mg subcutane-
ously followed by 300 mg every 4 weeks
Mechanism of action
Both IL-4 and IL-13 are key drivers of the Th2-mediated allergic inflammation. 
They synergistically act via a common receptor, IL-4Rα, to activate the signaling 
proteins [signal transducer and activator of transcription 6 (STAT6) and Janus 
kinase-1 (JAK1)]. IL-4 induces the immunoglobulin isotype class switch to IgE, 
promotes the Th2 phenotype, prevents T-cell apoptosis, renders the T-cells refrac-
tory to corticosteroids, and induces the expression of VCAM-1 on endothelial cells, 
subsequently promoting the recruitment of T-cells, eosinophils, basophils and 
monocytes. Gene polymorphisms in IL-4, IL − 13 and IL-4Rα have been associated 
with AD in certain populations.1 In the presence of IL-4 and IL-13, keratinocytes 
exhibit significantly less FLG gene expression, leading to epidermal barrier dys-
function. Dupilumab is a fully humanized monoclonal antibody against interleu-
kin-4 (IL-4) receptor-α (IL-4Rα) [5].
Dupilumab in AD
Dupilumab has been a major addition to the therapeutic armamentarium of 
moderate to severe refractory AD.
Administration of dupilumab leads to the following molecular changes:
1. downregulation of markers of epidermal proliferation
2. downregulation of inflammatory mediators
3. upregulation of structural proteins
4. upregulation of lipid metabolism proteins
5. upregulation of epidermal barrier proteins resulting in normalization  
of skin.
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6. Reduction in genes activating T cells
7. reduction in serum levels of CCL17 (or thymus and activation-regulated che-
mokine), a key regulator of Th2-mediated immunity and a specific biomarker 
of AD disease activity [6].
Mono-therapy or combined therapy with Dupilumab has shown to be benefi-
cial in the effective control of disease, improvement in skin lesions, significant 
reduction in pruritus and an improved quality of life of affected patients. Studies 
have shown that the transcriptome of skin lesions of AD resembled that of the 
non-lesional skin after only 4 weeks of treatment with Dupilumab. Many clini-
cal trials investigating the efficacy and safety of Dupilumab in AD have shown a 
rapid and marked improvement of disease activity, and a safe profile of adminis-
tration [1].
A phase 3 trial [7] conducted in 251 adolescents showed statistically signifi-
cant improvement in the signs, symptoms, and quality of life after 16 weeks of 
Dupilumab injection, with the 2-weekly regimen showing a better response.
In pediatric patients, a multi-centre review [8] done on 111 children showed ≥2 
point improvement in the Investigator Global Assessment (IGA) score in 64.3% 
patients after 9 weeks.
The mean dosage used in children was 8.7 mg/kg loading dose followed by 
5.1 mg/kg maintenance dose every other week.
Adverse effects reported include worsening of alcohol flushing; new regional 
dermatitis in face, conjunctivitis and eosinophilia have been reported with 
Dupilumab [9, 10].
2.2.2 Anti Il-4/Il-13 agents: Lebrikizumab and Tralokinumab
IL-13 is overexpressed in the skin lesions of AD patients and appears to nega-
tively regulate the expression of genes encoding crucial structural proteins (such 
as loricrin, involucrin), leading to be the impairment of the epidermal barrier. 
Lebrikizumab and Tralokinumab selectively target IL-13 and prevent the formation 
of the IL-13Rα1/IL-4Rα heterodimer receptor signaling complex [11]. Significant 
clinical improvement has been seen in moderate to severe AD in a small number of 
Phase 2 studies, with a good safety profile. However, concomitant topical cortico-
steroid therapy in enrolled patients limits data regarding their efficacy. Therefore, 
further studies are needed to confirm their beneficial effects in AD [1]. It is cur-
rently in Phase 3 trials. It is given subcutaneously every 4 weeks, but its effective 
dose is yet to be determined [12].
2.2.3 IL-31 directed therapy: Nemolizumab
It is a humanized monoclonal antibody against IL-31 receptor A. IL-31 is 
expressed predominantly by Th2 lymphocytes, functions to target keratinocytes, 
epithelial cells, eosinophils, basophils and monocytes. It is overexpressed in AD 
skin lesions [13]. A phase 3 randomized, double blind, placebo-controlled clinical 
trial [14] noted a significant clinical improvement profile in adult patients with 
refractory moderate to severe AD, as compared to the placebo group. However, the 
duration of the study was only for 16 weeks. Further studies are needed to confirm 
long-term efficacy and safety profile. The maximum efficacy has been seen with 
60 mg subcutaneous injections given every 4 weeks.
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2.3 Anti IL-12/IL-23 agent: Ustekinumab
Ustekinumab is a human immunoglobulin G1κ monoclonal antibody against 
the common p40-subunit shared by IL-12 and − 23. IL-23 is responsible for Th17 
cell development, and is associated with tissue damage in several inflammatory 
conditions. IL-23 levels positively correlates with the severity of atopic dermatitis 
among children. Results regarding the utility of Ustekinumab in the treatment of 
AD brought inconclusive results. While several case reports have suggested the 
efficacy of Ustekinumab in severe AD, some others show a moderate effect or a lack 
of it. This may be due to the multifactorial aetiopathology of the disease. Recently, 
Noda et al. [1] showed a predominant Th17 immune pattern in Asian AD patients. 
Such data is valuable for identifying individuals who are most likely to benefit from 
therapy. Further studies are needed to determine its efficacy and safety and the 
treatment of AD.
2.4 IL-22 blocker: Fezakinumab
IL-22 promotes epidermal hyperplasia and skin barrier dysfunction in AD. 
Fezankinumab is an anti IL-22 antibody. Phase 2 placebo-controlled studies have 
shown progressive and sustained clinical improvement of moderate-to-severe AD 
after 12 weeks of treatment. It is given intravenously with a loading dose of 600 mg 
followed by 300 mg every 2 weeks [1, 15].
2.5 Thymic stromal lymphopoietin directed therapy
TSLP is a pivotal pro-inflammatory cytokine in both acute and chronic skin 
lesions of AD. Tezepelumab is a human monoclonal antibody that prevents the 
interaction of thymic stromal lymphopoietin (TSLP) with its receptor [1]. Phase 2a 
trials [16] using 280 mg subcutaneous injections every 2 weeks showed an insig-
nificant improvement in the EASI and SCORAD values after 12 weeks of treatment. 
Therefore, it is unlikely to be a major treatment option in the near future.
2.6 JAK inhibitors
Targeting of the Janus kinase (JAK) and spleen tyrosine kinase (SYK) pathways 
attenuates signaling via multiple immune pathways (Th1, Th2, Th17 and Th22) and 
enhances keratinocyte differentiation [17]. Although these drugs have emerged as 
promising treatment options for AD, their long-term safety profiles are yet to be 
determined [4].
Tofacitinib shows specificity for JAK3, baricitinib mainly inhibits JAK1 and 
JAK2, upadacitinib, ruxolitinib and abrocitinib are selective for JAK1. Delgocitinib 
inhibits JAK1, JAK2 and JAK3. At present, baricitinib and upadacitinib are also at 
the final stages of clinical development for atopic dermatitis [18].
2.6.1 Tofacitinib
The first JAK inhibitor to be studied in humans, has been developed in both 
topical and oral formulations, although only oral tofacitinib is commercially 
available [4]. A single phase 2a randomized, double-blind, vehicle-controlled 
study on 69 adults with mild-to-moderate AD showed significant improve-
ment(−81.7% vs. −29.9%) in the EASI score after 4 weeks of applying 2% 
tofacitinb ointment [19, 20].
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2.6.2 Delgocitinib
0.025% and 0.5% ointment has shown encouraging results in recent Phase 3 
[21] studies in adult patients, and Phase 2a studies [22] in pediatric patients with 
moderate to severe AD up to 4 weeks and 28 weeks respectively, with no serious side 
effects
2.6.3 Oral Abrocitinib
Oral Abrocitinib was evaluated in a phase 3 double-blind placebo-controlled 
trial, [23] and was effective and well tolerated in adolescents and adults with 
moderate-to-severe atopic dermatitis. In this trial, 387 patients (aged ≥12 years; 43% 
women) with moderate-to-severe atopic dermatitis (60% with moderate disease; 
40% with severe disease) were randomly assigned (2:2:1) to receive oral abrocitinib 
100 mg, 200 mg, or placebo once a day. At week 12, 37 (24%) of 156 patients in the 
abrocitinib 100 mg group and 67 (44%) of 154 patients in the abrocitinib 200 mg 
group had achieved an Investigator Global Assessment response of clear or almost 
clear (score 0–1) compared with six (8%) of 77 patients in the placebo group, and 62 
(40%) of 156 patients in the abrocitinib 100 mg group and 96 (62%) of 154 patients 
in the abrocitinib 200 mg group achieved a 75% improvement or more in Eczema 
Area and Severity Index (EASI) score from baseline, compared with nine (12%) of 
77 patients in the placebo group. This seems to be a promising future option for AD.
2.6.4 Baricitinib
Phase 2 RCT [24] in 124 adults with 2 mg and 4 mg qd dose of Baricitinib 
showed significant reduction in pruritus and inflammation after 16 weeks. The 
common adverse effects noted were headache, increased creatine phosphokinase 
levels and nasopharyngitis.
2.6.5 Ruxolitinib
Phase 2 RCT was conducted in 252 adults with AD, to study the efficacy of 0.15% 
cream qd, 0.5% RUX cream qd, 1.5% RUX cream qd and 1.5% RUX cream bid. The 
study showed significant symptomatic improvement after 4 weeks of application, 
which was sustained for 12 weeks, with good tolerability and no major adverse 
effects [19, 25].
2.7 Miscellaneous
Studies with the following drugs have either failed to demonstrate a significant 
improvement or are currently under phase 2 trials:
• Mepolizumab-a humanized monoclonal anti-IL-5 antibody
• Rituximab - a chimeric monoclonal antibody against CD20
• Tumor necrosis-α factor/receptor (TNF-α) inhibitors such as Infliximab, 
Etanercept, and Adalimumab.
• High-dose intravenous immunoglobulins (IVIGs)
• Anti IL-17: Secukinumab
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• Anti IL-6: Tocilizumab
• Recombinant human interferon-γ (rhIFN-γ)
• Natural AhR (therapeutic aryl hydrocarbon receptor) modulating agent: 
Tapinarof
• T-cell modulating agents (Efalizumab and Alefacept) [1]
• Anti IL-1α-Bermekimab [26].
3. Conclusion
Biologicals offer exciting prospects in the future management strategies for 
atopic dermatitis. However, the paucity of multicentric, large-scale, randomized 
trials, a high cost of treatment, along with a lack of comparative studies with the 
existing modalities of treatment are the major obstacles to their large scale use in 
clinical practice. Therefore, more studies with a larger sample size and longer follow 
up periods are needed to determine their efficacy and long-term safety profiles. 
Although Dupilumab is currently the only biological drug approved by the FDA 
for atopic dermatitis, other biologicals have also shown promising results and are 
expected to be a major part of the therapeutic armamentarium for atopic dermatitis 
in the near future.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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